Search Results - "Ott, P. A."

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study by Hansen, A.R., Massard, C., Ott, P.A., Haas, N.B., Lopez, J.S., Ejadi, S., Wallmark, J.M., Keam, B., Delord, J.-P., Aggarwal, R., Gould, M., Yang, P., Keefe, S.M., Piha-Paul, S.A.

“…Patients with castration-resistant prostate cancer derive only modest clinical benefit from available therapies. Blockade of the inhibitory programmed death 1…”
Get full text

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal by Ott, P.A., Piha-Paul, S.A., Munster, P., Pishvaian, M.J., van Brummelen, E.M.J., Cohen, R.B., Gomez-Roca, C., Ejadi, S., Stein, M., Chan, E., Simonelli, M., Morosky, A., Saraf, S., Emancipator, K., Koshiji, M., Bennouna, J.

“…Safety and efficacy of pembrolizumab, a humanized programmed death 1 monoclonal antibody, was assessed in KEYNOTE-028, a multicohort, phase Ib trial for…”
Get full text

Adjuvant immunotherapy for melanoma patients: progress and opportunities by Sussman, T.A., Ott, P.A.

“…The majority of patients who are diagnosed with cutaneous melanoma are candidates for surgical resection and thus curable from their disease. However, the risk…”
Get full text

A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer by Ott, P.A., Govindan, R., Naing, A., Friedlander, T.W., Margolin, K., Lin, J.J., Bhardwaj, N., Hellman, M.D., Srinivasan, L., Greshock, J., Moles, M., Gaynor, R.B., Goldstein, M.J., Hu-Lieskovan, S.

Get full text

Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors by Boni, V, Garcia-Corbacho, J, Ott, P A, Cho, D C, Autio, K A, Uboha, N, Spira, A I, Humphrey, R, Will, M, Naing, A, Thistlethwaite, F, de Vries, E G E, Arkenau, H-T

Get full text

A novel framework for evaluating biomarker response relationships in immuno-oncology (IO) by Evelhoch, J.L., Mogg, R., Cristescu, R., Aurora-Garg, D., Chow, L.Q., Loi, S., Catenacci, D.V.T., Matulonis, U.A., Ott, P.A., Antonarakis, E.S., Poehlein, C.H., Joe, A., Keefe, S.M., Kang, P., Karantza, V., Cheng, J., Rubin, E.H.

Get full text

Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs) by Hamid, O., Hu-Lieskovan, S., Ros, W., Diab, A., El-Khoueiry, A.B., Thompson, J.A., Eskens, F.A., Spano, J.-P., Angevin, E., Rizvi, N.A., Wasser, J.S., Ott, P.A., Chiappori, A., Joh, T., Krupka, H.I., Potluri, S., Wang, X., Ganguli, B.J., Chou, J., Doi, T.

Get full text

Cost of cardiac care in the three years after coronary catheterization in a contained care system : Critical determinants and implications by ELLIS, S. G, BROWN, K. J, ELLERT, R, HOWELL, G. L, MILLER, D. P, FLOWERS, N. M, OTT, P. A, KEYS, T, LOOP, F. D, TOPOL, E. J

“…We sought to determine the clinical, angiographic, treatment and outcome correlates of the intermediate-term cost of caring for patients with suspected…”
Get full text

Immediate results of combined treatment for soft tissue sarcomas including intraoperative radiation therapy by Ott, P A, Privalov, A V, Vazhenin, A V, Nadvikova, E A, Lukina, E Iu, Komissarov, A V, Zabolotskaia, E G

“…Nowadays the most popular and justified, from oncological positions, method of treatment for soft tissue sarcomas is a combined approach with the use of…”
Get more information

How physicians can help create useful clinical practice guidelines by Achkar, E, Block, V J, Ott, P A

Get more information

The cytokine signature of MOG-specific CD4 cells in the EAE of C57BL/6 mice by Hofstetter, Harald H., Karulin, Alexey Y., Forsthuber, Thomas G., Ott, Patrick A., Tary-Lehmann, Magdalena, Lehmann, Paul V.

“…Experimental allergic encephalomyelitis (EAE) is an animal model of multiple sclerosis. While EAE is mediated by the cytokines produced by specific T cells,…”
Get full text

T cells recognize multiple GAD65 and proinsulin epitopes in human type 1 diabetes, suggesting determinant spreading by Ott, Patrick A, Dittrich, Marcus T, Herzog, Bernhard A, Guerkov, Robert, Gottlieb, Peter A, Putnam, Amy L, Durinovic-Bello, Ivana, Boehm, Bernhard O, Tary-Lehmann, Magdalena, Lehmann, Paul V

“…Human type 1 diabetes is thought to be mediated by autoreactive T cells specific for antigens expressed by pancreatic beta cells. However, it is unclear which…”
Get full text

CD28 costimulation enhances the sensitivity of the ELISPOT assay for detection of antigen-specific memory effector CD4 and CD8 cell populations in human diseases by Ott, Patrick A, Berner, Beate R, Herzog, Bernhard A, Guerkov, Robert, Yonkers, Nicole L, Durinovic-Bello, Ivana, Tary-Lehmann, Magdalena, Lehmann, Paul V, Anthony, Donald D

“…The frequencies of antigen-specific memory cells are often low in chronic disease states related to infection and autoimmunity, making detection of such…”
Get full text

IL-2 absorption affects IFN-γ and IL-5, but not IL-4 producing memory T cells in double color cytokine ELISPOT assays by Quast, Stefan, Zhang, Wenji, Shive, Carey, Kovalovski, Damian, Ott, Patrick A., Herzog, Bernhard A., Boehm, Bernhard O., Tary-Lehmann, Magdalena, Karulin, Alexey Y., Lehmann, Paul V.

“…Cytokine assays are gaining increasing importance for human immune monitoring because they reliably detect antigen-specific T cells in primary PBMC, even at…”
Get full text

Islet-cell antigen-reactive T cells show different expansion rates and Th1/Th2 differentiation in type 1 diabetic patients and healthy controls by Ott, Patrick A., Herzog, Bernhard A., Quast, Stefan, Hofstetter, Harald H., Boehm, Bernhard O., Tary-Lehmann, Magdalena, Durinovic-Bello, Ivana, Berner, Beate R., Lehmann, Paul V.

“…The low frequency of islet-cell antigen-reactive T cells in type 1 diabetes makes their direct measurement difficult. Commonly used in vitro expansion could…”
Get full text

Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study by Shapira-Frommer, Ronnie, Mileshkin, Linda, Manzyuk, Ludmila, Penel, Nicolas, Burge, Matthew, Piha-Paul, Sarina A, Girda, Eugenia, Lopez Martin, Jose A, van Dongen, Marloes G J, Italiano, Antoine, Xu, Lei, Jin, Fan, Norwood, Kevin, Ott, Patrick A

“…Treatment options for advanced vulvar cancer are limited. We evaluated pembrolizumab monotherapy in patients with advanced vulvar squamous cell carcinoma (SCC)…”
Get full text

435PPreliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors by Boni, V, Garcia-Corbacho, J, Ott, P A, Cho, D C, Autio, K A, Uboha, N, Spira, A I, Humphrey, R, Will, M, Naing, A, Thistlethwaite, F, de Vries, E G E, Arkenau, H-T

Get full text

1127OA personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer by Ott, P A, Govindan, R, Naing, A, Friedlander, T W, Margolin, K, Lin, J J, Bhardwaj, N, Hellman, M D, Srinivasan, L, Greshock, J, Moles, M, Gaynor, R B, Goldstein, M J, Hu-Lieskovan, S

Get full text

1044PPembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study by O'Malley, D, Marabelle, A, De Jesus-Acosta, A, Piha-Paul, S A, Arkhipov, A, Longo, F, Motola-Kuba, D, Shapira-Frommer, R, Geva, R, Rimel, B J, Lopez-Martin, J A, Hansen, A R, Mehnert, J M, Chen, X, Jin, F, Norwood, K, Ott, P A

“…Abstract Background Pembrolizumab (pembro) provides durable responses in patients (pts) with MSI-H cancers and is approved in the US/Japan for the treatment of…”
Get full text

1184PPharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs) by Hamid, O, Hu-Lieskovan, S, Ros, W, Diab, A, El-Khoueiry, A B, Thompson, J A, Eskens, F A, Spano, J-P, Angevin, E, Rizvi, N A, Wasser, J S, Ott, P A, Chiappori, A, Joh, T, Krupka, H I, Potluri, S, Wang, X, Ganguli, B J, Chou, J, Doi, T

Get full text